[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-331244-105":59,"doc-detail-331244-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","autoantibodies-in-cancer-a-systematic-review-of-their-clinical-role-in-the-most-prevalent-cancers","Autoantibodies in cancer - a systematic review of their clinical role in the most prevalent cancers","","Blood autoantibodies, once linked mainly to autoimmune diseases, are increasingly supported across many cancer types and are being explored for clinical use. Their potential includes early detection, prognosis, and monitoring of patients. The review summarizes techniques for discovery and validation, highlights autoantibody panels confirmed in multiple reports for highly incident cancers, and discusses newly developed detection kits, including breast and lung cancer, plus screening-driven therapeutic target opportunities. It also addresses remaining barriers to routine clinical implementation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/autoantibodies-in-cancer-a-systematic-review-of-their-clinical-role-in-the-most-prevalent-cancers/331244/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/autoantibodies-in-cancer-a-systematic-review-of-their-clinical-role-in-the-most-prevalent-cancers/331244.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How are cancer autoantibodies expected to support clinical practice?","Question",{"text":112,"@type":113},"Cancer autoantibodies are explored as biomarkers for early detection, prognosis, and monitoring, with measurement from minimally invasive blood samples.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which techniques does the review describe for identifying and validating autoantibodies?",{"text":117,"@type":113},"The review discusses discovery and validation methods, including protein, phage, and peptide microarrays, phage display, next-generation sequencing (NGS), and mass spectrometry.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence and panels does the review emphasize for prevalent cancers?",{"text":121,"@type":113},"It details autoantibody panels verified across at least two different reports and notes that these may be more likely specific to the four most incident cancers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},331244,1791405796,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":4},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Review  \nPUBLISHED 21 August 2024  \nDOI 10.3389/fimmu.2024.1455602  \nOPEN ACCESS  \nEDITED BY  \nOscar J. Cordero,  \nUniversity of Santiago de Compostela, Spain  \nREVIEWED BY  \nRafael Gongora,  \nUniversity of Salamanca, Spain Yi Huang,  \nFujian Provincial Hospital, China  \n*CORRESPONDENCE Rodrigo Barderas  \n [r.barderasm@isciii.es](r.barderasm@isciii.es)  \n†These authors have contributed equally to this work  \nRECEIVED 27 June 2024  \nACCEPTED 31 July 2024  \nPUBLISHED 21 August 2024  \nCITATION  \nMontero-Calle A, Garranzo-Asensio M, Moreno-Casbas MT, Campuzano S and Barderas R (2024) Autoantibodies in cancer:  \na systematic review of their clinical role in the most prevalent cancers.  \nFront. Immunol. 15:1455602 .  \ndoi: 10.3389/fimmu.2024.1455602  \nCOPYRIGHT  \n© 2024 Montero-Calle, Garranzo-Asensio, Moreno-Casbas, Campuzano and Barderas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAutoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers  \nAna Montero-Calle 1†, Mar ´ıa Garranzo-Asensio 1†, Maria Teresa Moreno-Casbas 2,3, Susana Campuzano 4 and Rodrigo Barderas 1,3*  \n1Chronic Disease Programme (UFIEC), Instituto de Salud Carlos III, Madrid, Spain, 2 Investe´ n-isciii, Instituto de Salud Carlos III, Madrid, Spain, 3 Biomedical Research Center Network for Frailty and Healthy Ageing (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain, 4 Departamento de Qumica Analtica, Facultad de CC. Qumicas, Universidad Complutense de Madrid, Madrid, Spain  \nAlthough blood autoantibodies were initially associated with autoimmune diseases, multiple evidence have been accumulated showing their presence in many types of cancer. This has opened their use in clinics, since cancer autoantibodies might be useful for early detection, prognosis, and monitoring of cancer patients. In this review, we discuss the different techniques available for their discovery and validation. Additionally, we discuss here in detail those autoantibody panels verified in at least two different reports that should be more likely to be specificof each of the four most incident cancers. We also report the recent developed kits for breast and lung cancer detection mostly based on autoantibodies and the identification of novel therapeutic targets because of the screening of the cancer humoral immune response. Finally, we discuss unsolved issues that still need to be addressed for the implementation of cancer autoantibodies in clinical routine for cancer diagnosis, prognosis, and/or monitoring.  \nKEYWORDS  \nhumoral immune response, autoantibodies, cancer autoantibodies, colorectal cancer, breast cancer, lung cancer, prostate cancer, proteomics  \n1 Introduction  \nThe first reports describing the existence of a link between an immune response and cancer through autoantibodies were published in the 1950s. Since then, there has been growing interest in cancer autoantibodies. They are not only used as biomarkers to indicate the occurrence and development of cancer, disease response, and progression (1–3), but also to characterize the humoral immune response. This response is useful for identifying druggable targets and developing new cancer therapies. These therapies include potential  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nimmunotherapy drugs, tumor-infiltrating B cells, and stimulation of the intrinsic humoral immune system with radiation in metastatic disease, known as the abscopal effect (4–7) .  \nThis humoral immune response acts against self-proteins that are altered during the formation and progression of ca","cbCaiuexDYakaJ7N","https://ap.wps.com/l/cbCaiuexDYakaJ7N","pdf",4897583,"English","# Introduction\n## Immune response and origins of cancer autoantibodies\n## Clinical relevance as biomarkers\n## High-throughput discovery technologies\n## Validation and cancer-specific targets","[{\"question\":\"How are cancer autoantibodies expected to support clinical practice?\",\"answer\":\"Cancer autoantibodies are explored as biomarkers for early detection, prognosis, and monitoring, with measurement from minimally invasive blood samples.\"},{\"question\":\"Which techniques does the review describe for identifying and validating autoantibodies?\",\"answer\":\"The review discusses discovery and validation methods, including protein, phage, and peptide microarrays, phage display, next-generation sequencing (NGS), and mass spectrometry.\"},{\"question\":\"What evidence and panels does the review emphasize for prevalent cancers?\",\"answer\":\"It details autoantibody panels verified across at least two different reports and notes that these may be more likely specific to the four most incident cancers.\"}]","Autoantibodies in cancer - a systematic review of their clinical role in the most prevalent cancers | PDF",1789992378]